Abililfy Manufacturers Are Off the Hook in Whistleblower Lawsuit
A six-year legal battle has finally ended for drugmakers Bristol-Meyer Squibb (BMS) and Otsuka as a judicial panel recently made a 2 to 1 decision not to revive a whistleblower lawsuit filed by two former employees.In U.S. v. Bristol Meyers Squibb Co., the Sixth Circuit ruled that the...
“Exponential Growth” Expected for the Antipsychotic Market; Meanwhile, Skilled Nursing Reduces Need for Such Drugs
A recent report from Allied Market Research has provided some news that is giving CEOs and shareholders in major pharmaceutical companies some reason to celebrate. Because of the rise in the number of patients suffering mental illness, primarily schizophrenia, the market for neuroleptic and anti-psychotic medications such as Abilify...
Abilify: New Study Indicates the Benefits Aren’t Worth the Risks
For some time, it has been known that the anti-depressant drug Abilify causes people who take it to behave in reckless, impulsive ways. In these situations, manufacturers of such harmful prescription medications argue that the benefits of the product outweigh the risks, often citing self-funded research studies. However, a...
Abilify Makers Join Forces With Manufacturer of the World’s First Ingestible Medical Monitor
Undeterred by a growing number of lawsuits over the antipsychotic medication Abilify, drugmaker Otsuka Pharmaceutical Company and its partners at Bristol-Meyers continue to seek new markets, promoting the drug for off-label uses ranging from autism to dementia and eating disorders.Bristol-Meyers even wound up paying out a $19.5 million...
Despite Lawsuits and Demonstrated Dangers, States Continue to Spend Millions on Abilify and Other Anti-Psychotic Drugs for Juvenile Offenders
In 1999, the Center for Science and Law reported that a large number of anti-psychotic medications were being given to juvenile offenders – regardless of whether or not they had actually been diagnosed with a mental disorder. It was described as “a mere replacement of the old-fashioned use of...
Treating Autism With Abilify: Is It a Good Idea?
In 2009, the FDA approved Abilify (aripiprazole) for treating irritability in autistic children and youth up to age 17. In a press release issued at the time, manufacturer Bristol-Meyers Squibb stated that Abilify – normally used to treat bipolar disorder, schizophrenia and depression – should be used in conjunction...
Former Convicted Arms Smuggler and Gun Runner Blames Abilify For His Behavior
Can Abilify, demonstrated to cause uncontrollable, impulsive and destructive behavior, also cause the user to engage in criminal behavior? A former gun-runner and convicted fraudster believes so – and is going to court in order to prove it.
Many people don't remember the name Efraim Diveroli today, but his life...
Abilify is a Boon For Casinos, Hotels, Divorce Lawyers, Junk Food Purveyors and Credit Card Companies
It is being established that the anti-psychotic medication Abilify (aripiprazole) has the potential to cause irrational, compulsive behaviors in patients who take it. One of the tragedies is that neither patients nor physicians had any idea of the connection – at least in the U.S. One thing is certain:...
Why Were Abilify Gambling Warnings Issued in Europe But Not In The U.S.?
Bradley and Denise Meyer have filed one of the increasing number of lawsuits against Abilify makers Bristol-Meyer Squibb and Otsuka Pharmaceuticals. Their attorneys have filed a motion with the U.S. Judicial Panel on Multidistrict Litigation, asking that the trials be moved to a federal court in Northern Florida. However,...
Abilify and the link to Tardive Dyskinesia
Poor impulse control (particularly compulsive gambling) is one of the main side effects of the “new generation” neuroleptic medication Abilify. That has been the cause of action in recent lawsuits against drug manufacturers Otksuka Pharmaceuticals and Bristol-Meyers Squibb. However, it is not the most serious side effect. Two years...